Gilead's single-pill combo BIC/FTC/TAF matches multi-tablet bPI regimen in late-stage HIV study

|About: Gilead Sciences, Inc. (GILD)|By:, SA News Editor

A Phase 3 clinical trial, Study 1878, evaluating Gilead Sciences' (GILD -1.2%) single-tablet, fixed-dose combination of bictegravir (50 mg) and emtricitabine/tenofovir alafenamide (200 mg/25 mg) (BIC/FTC/TAF) for the treatment of adults with HIV-1 infection who switched from a multi-tablet regimen containing a boosted protease inhibitor (bPI) to BIC/FTC/TAF demonstrated non-inferiority after 48 weeks. The data will be presented at IDWeek in San Diego later this week.

No treatment-emergent resistance was observed over the 48-week period.

Eric Daar, MD, Chief of the Division of HIV Medicine at Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center and lead author of Study 1878 says, “These data demonstrate the potential of BIC/FTC/TAF to match the efficacy of a boosted protease inhibitor regimen while also offering a high barrier to resistance and fewer interactions with other drugs. The findings, along with data from three other Phase 3 studies in both treatment-experienced and treatment-naïve patients, suggest that the investigational regimen of BIC/FTC/TAF may be appropriate for a broad range of people living with HIV.”

Gilead's marketing applications in the U.S. and Europe are currently under review. The FDA's action date is February 12, 2018.

Previously: FDA grants accelerated review of Gilead's NDA for HIV med BIC/FTC/TAF, action date February 12 (Aug. 10)

Subscribe for full text news in your inbox